LOLLI, CRISTIAN
LOLLI, CRISTIAN
Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study
2024 Casadei C.; Scarpi E.; Conteduca V.; Gurioli G.; Cursano M.C.; Brighi N.; Lolli C.; Schepisi G.; Basso U.; Fornarini G.; Bleve S.; Farolfi A.; Altavilla A.; Burgio S.L.; Giunta E.F.; Gianni C.; Filograna A.; Ulivi P.; Olmos D.; Castro E.; De Giorgi U.
Impact of the time interval between primary or interval surgery and adjuvant chemotherapy in ovarian cancer patients
2023 Farolfi A.; Petracci E.; Gurioli G.; Tedaldi G.; Casanova C.; Arcangeli V.; Amadori A.; Rosati M.; Stefanetti M.; Burgio S.L.; Cursano M.C.; Lolli C.; Zampiga V.; Cangini I.; Schepisi G.; De Giorgi U,
Grade group system and plasma androgen receptor status in the first line treatment for metastatic castration resistant prostate cancer
2022 Cursano M.C.; Conteduca V.; Scarpi E.; Gurioli G.; Casadei C.; Gargiulo S.; Altavilla A.; Lolli C.; Vincenzi B.; Tonini G.; Santini D.; De Giorgi U.
An update on our ability to monitor castration-resistant prostate cancer dynamics with cell-free DNA
2021 Conteduca V.; Brighi N.; Conteduca D.; Bleve S.; Gianni C.; Schepisi G.; Iaia M.L.; Gurioli G.; Lolli C.; De Giorgi U.
Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcome
2021 Conteduca V.; Scarpi E.; Caroli P.; Lolli C.; Gurioli G.; Brighi N.; Poti G.; Farolfi A.; Altavilla A.; Schepisi G.; Matteucci F.; Paganelli G.; De Giorgi U.
Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging
2021 Conteduca V.; Poti G.; Caroli P.; Russi S.; Brighi N.; Lolli C.; Schepisi G.; Romeo A.; Matteucci F.; Paganelli G.; Marchetti P.; De Giorgi U.
Immunotherapy and its development for gynecological (Ovarian, endometrial and cervical) tumors: From immune checkpoint inhibitors to chimeric antigen receptor (car)-T cell therapy
2021 Schepisi G.; Casadei C.; Toma I.; Poti G.; Iaia M.L.; Farolfi A.; Conteduca V.; Lolli C.; Ravaglia G.; Brighi N.; Altavilla A.; Martinelli G.; De Giorgi U.
Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study
2021 Conteduca V.; Wetterskog D.; Castro E.; Scarpi E.; Romero-Laorden N.; Gurioli G.; Jayaram A.; Lolli C.; Schepisi G.; Wingate A.; Casadei C.; Lozano R.; Brighi N.; Aragon I.M.; Marin-Aguilera M.; Gonzalez-Billalabeitia E.; Mellado B.; Olmos D.; Attard G.; De Giorgi U.
Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patients
2021 Conteduca V.; Scarpi E.; Wetterskog D.; Brighi N.; Ferroni F.; Rossi A.; Romanel A.; Gurioli G.; Bleve S.; Gianni C.; Schepisi G.; Lolli C.; Cortesi P.; Matteucci F.; Barone D.; Paganelli G.; Demichelis F.; Beltran H.; Attard G.; De Giorgi U.
The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectives
2021 Brighi N.; Conteduca V.; Lolli C.; Gurioli G.; Schepisi G.; Palleschi M.; Mariotti M.; Casadei C.; De Giorgi U.
A comprehensive review of the role of immune checkpoint inhibitors in elderly patients affected by renal cell carcinoma
2020 Lolli C.; Altavilla A.; Conteduca V.; Farolfi A.; Casadei C.; Schepisi G.; Banna G.L.; De Giorgi U.
Immune modulation in prostate cancer patients treated with androgen receptor (Ar)-targeted therapy
2020 Conteduca V.; Caffo O.; Scarpi E.; Sepe P.; Galli L.; Fratino L.; Maines F.; Chiuri V.E.; Santoni M.; Zanardi E.; Massari F.; Toma I.; Lolli C.; Schepisi G.; Sbrana A.; Kinspergher S.; Cursano M.C.; Casadei C.; Modonesi C.; Santini D.; Procopio G.; De Giorgi U.
Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide
2020 Gurioli G.; Conteduca V.; Lolli C.; Schepisi G.; Gargiulo S.; Altavilla A.; Casadei C.; Scarpi E.; De Giorgi U.
Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell Tumors
2020 Schepisi G.; Conteduca V.; Casadei C.; Gurioli G.; Rossi L.; Galla V.; Cursano M.C.; Brighi N.; Lolli C.; Menna C.; Farolfi A.; Burgio S.L.; Altavilla A.; Martinelli G.; De Giorgi U.
Prognostic Role of Systemic Inflammatory Indexes in Germ Cell Tumors Treated With High-Dose Chemotherapy
2020 Cursano M.C.; Kopf B.; Scarpi E.; Menna C.; Casadei C.; Schepisi G.; Lolli C.; Altavilla A.; Galla V.; Santini D.; Tonini G.; Chovanec M.; Mego M.; De Giorgi U.
CAR-T cell therapy: A potential new strategy against prostate cancer
2019 Schepisi G.; Cursano M.C.; Casadei C.; Menna C.; Altavilla A.; Lolli C.; Cerchione C.; Paganelli G.; Santini D.; Tonini G.; Martinelli G.; De Giorgi U.
Immune-checkpoint inhibitors and the importance of concomitant medications: focus on antibiotics
2019 Casadei, C; Lolli, C; Farolfi, A
Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
2019 Conteduca V.; Jayaram A.; Romero-Laorden N.; Wetterskog D.; Salvi S.; Gurioli G.; Scarpi E.; Castro E.; Marin-Aguilera M.; Lolli C.; Schepisi G.; Maugeri A.; Wingate A.; Farolfi A.; Casadio V.; Medina A.; Puente J.; Vidal M.J.M.; Morales-Barrera R.; Villa-Guzman J.C.; Hernando S.; Rodriguez-Vida A.; Gonzalez-del-Alba A.; Mellado B.; Gonzalez-Billalabeitia E.; Olmos D.; Attard G.; De Giorgi U.
Plasma androgen receptor in prostate cancer
2019 Conteduca V.; Gurioli G.; Brighi N.; Lolli C.; Schepisi G.; Casadei C.; Burgio S.L.; Gargiulo S.; Ravaglia G.; Rossi L.; Altavilla A.; Farolfi A.; Menna C.; Colangione S.P.; Pulvirenti M.; Romeo A.; De Giorgi U.
Psychosocial issues in long-term survivors of testicular cancer
2019 Schepisi G.; De Padova S.; De Lisi D.; Casadei C.; Meggiolaro E.; Ruffilli F.; Rosti G.; Lolli C.; Ravaglia G.; Conteduca V.; Farolfi A.; Grassi L.; De Giorgi U.
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study | Casadei C.; Scarpi E.; Conteduca V.; Gurioli G.; Cursano M.C.; Brighi N.; Lolli C.; Schepisi G.; ...Basso U.; Fornarini G.; Bleve S.; Farolfi A.; Altavilla A.; Burgio S.L.; Giunta E.F.; Gianni C.; Filograna A.; Ulivi P.; Olmos D.; Castro E.; De Giorgi U. | 2024-01-01 | EUROPEAN UROLOGY OPEN SCIENCE | - | 1.01 Articolo in rivista | Inherited Mutations in DNA Damage Repair Genes from Meet-URO 10 Study.pdf |
| Impact of the time interval between primary or interval surgery and adjuvant chemotherapy in ovarian cancer patients | Farolfi A.; Petracci E.; Gurioli G.; Tedaldi G.; Casanova C.; Arcangeli V.; Amadori A.; Rosati M....; Stefanetti M.; Burgio S.L.; Cursano M.C.; Lolli C.; Zampiga V.; Cangini I.; Schepisi G.; De Giorgi U, | 2023-01-01 | FRONTIERS IN ONCOLOGY | - | 1.01 Articolo in rivista | fonc-13-1221096.pdf; Table_1 .docx |
| Grade group system and plasma androgen receptor status in the first line treatment for metastatic castration resistant prostate cancer | Cursano M.C.; Conteduca V.; Scarpi E.; Gurioli G.; Casadei C.; Gargiulo S.; Altavilla A.; Lolli C....; Vincenzi B.; Tonini G.; Santini D.; De Giorgi U. | 2022-01-01 | SCIENTIFIC REPORTS | - | 1.01 Articolo in rivista | - |
| An update on our ability to monitor castration-resistant prostate cancer dynamics with cell-free DNA | Conteduca V.; Brighi N.; Conteduca D.; Bleve S.; Gianni C.; Schepisi G.; Iaia M.L.; Gurioli G.; L...olli C.; De Giorgi U. | 2021-01-01 | EXPERT REVIEW OF MOLECULAR DIAGNOSTICS | - | 1.01 Articolo in rivista | - |
| Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcome | Conteduca V.; Scarpi E.; Caroli P.; Lolli C.; Gurioli G.; Brighi N.; Poti G.; Farolfi A.; Altavil...la A.; Schepisi G.; Matteucci F.; Paganelli G.; De Giorgi U. | 2021-01-01 | MOLECULAR ONCOLOGY | - | 1.01 Articolo in rivista | Molecular Oncology - 2021 - Conteduca - Combining liquid biopsy and functional imaging analysis in metastatic.pdf; Supplementary materials.zip |
| Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging | Conteduca V.; Poti G.; Caroli P.; Russi S.; Brighi N.; Lolli C.; Schepisi G.; Romeo A.; Matteucci... F.; Paganelli G.; Marchetti P.; De Giorgi U. | 2021-01-01 | THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | - | 1.01 Articolo in rivista | 1758835920987654.pdf |
| Immunotherapy and its development for gynecological (Ovarian, endometrial and cervical) tumors: From immune checkpoint inhibitors to chimeric antigen receptor (car)-T cell therapy | Schepisi G.; Casadei C.; Toma I.; Poti G.; Iaia M.L.; Farolfi A.; Conteduca V.; Lolli C.; Ravagli...a G.; Brighi N.; Altavilla A.; Martinelli G.; De Giorgi U. | 2021-01-01 | CANCERS | - | 1.01 Articolo in rivista | cancers-13-00840-v2.pdf |
| Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study | Conteduca V.; Wetterskog D.; Castro E.; Scarpi E.; Romero-Laorden N.; Gurioli G.; Jayaram A.; Lol...li C.; Schepisi G.; Wingate A.; Casadei C.; Lozano R.; Brighi N.; Aragon I.M.; Marin-Aguilera M.; Gonzalez-Billalabeitia E.; Mellado B.; Olmos D.; Attard G.; De Giorgi U. | 2021-01-01 | EUROPEAN JOURNAL OF CANCER | - | 1.01 Articolo in rivista | - |
| Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patients | Conteduca V.; Scarpi E.; Wetterskog D.; Brighi N.; Ferroni F.; Rossi A.; Romanel A.; Gurioli G.; ...Bleve S.; Gianni C.; Schepisi G.; Lolli C.; Cortesi P.; Matteucci F.; Barone D.; Paganelli G.; Demichelis F.; Beltran H.; Attard G.; De Giorgi U. | 2021-01-01 | INTERNATIONAL JOURNAL OF CANCER | - | 1.01 Articolo in rivista | - |
| The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectives | Brighi N.; Conteduca V.; Lolli C.; Gurioli G.; Schepisi G.; Palleschi M.; Mariotti M.; Casadei C....; De Giorgi U. | 2021-01-01 | CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | - | 1.01 Articolo in rivista | - |
| A comprehensive review of the role of immune checkpoint inhibitors in elderly patients affected by renal cell carcinoma | Lolli C.; Altavilla A.; Conteduca V.; Farolfi A.; Casadei C.; Schepisi G.; Banna G.L.; De Giorgi U. | 2020-01-01 | CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | - | 1.01 Articolo in rivista | - |
| Immune modulation in prostate cancer patients treated with androgen receptor (Ar)-targeted therapy | Conteduca V.; Caffo O.; Scarpi E.; Sepe P.; Galli L.; Fratino L.; Maines F.; Chiuri V.E.; Santoni... M.; Zanardi E.; Massari F.; Toma I.; Lolli C.; Schepisi G.; Sbrana A.; Kinspergher S.; Cursano M.C.; Casadei C.; Modonesi C.; Santini D.; Procopio G.; De Giorgi U. | 2020-01-01 | JOURNAL OF CLINICAL MEDICINE | - | 1.01 Articolo in rivista | Journal Clinical Medicine [Conteduca].pdf |
| Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide | Gurioli G.; Conteduca V.; Lolli C.; Schepisi G.; Gargiulo S.; Altavilla A.; Casadei C.; Scarpi E....; De Giorgi U. | 2020-01-01 | FRONTIERS IN ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell Tumors | Schepisi G.; Conteduca V.; Casadei C.; Gurioli G.; Rossi L.; Galla V.; Cursano M.C.; Brighi N.; L...olli C.; Menna C.; Farolfi A.; Burgio S.L.; Altavilla A.; Martinelli G.; De Giorgi U. | 2020-01-01 | FRONTIERS IN ONCOLOGY | - | 1.01 Articolo in rivista | fonc-10-565857.pdf |
| Prognostic Role of Systemic Inflammatory Indexes in Germ Cell Tumors Treated With High-Dose Chemotherapy | Cursano M.C.; Kopf B.; Scarpi E.; Menna C.; Casadei C.; Schepisi G.; Lolli C.; Altavilla A.; Gall...a V.; Santini D.; Tonini G.; Chovanec M.; Mego M.; De Giorgi U. | 2020-01-01 | FRONTIERS IN ONCOLOGY | - | 1.01 Articolo in rivista | - |
| CAR-T cell therapy: A potential new strategy against prostate cancer | Schepisi G.; Cursano M.C.; Casadei C.; Menna C.; Altavilla A.; Lolli C.; Cerchione C.; Paganelli ...G.; Santini D.; Tonini G.; Martinelli G.; De Giorgi U. | 2019-01-01 | JOURNAL FOR IMMUNOTHERAPY OF CANCER | - | 1.01 Articolo in rivista | - |
| Immune-checkpoint inhibitors and the importance of concomitant medications: focus on antibiotics | Casadei, C; Lolli, C; Farolfi, A | 2019-01-01 | ANNALS OF TRANSLATIONAL MEDICINE | - | 1.04 Replica / breve intervento (e simili) | - |
| Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer | Conteduca V.; Jayaram A.; Romero-Laorden N.; Wetterskog D.; Salvi S.; Gurioli G.; Scarpi E.; Cast...ro E.; Marin-Aguilera M.; Lolli C.; Schepisi G.; Maugeri A.; Wingate A.; Farolfi A.; Casadio V.; Medina A.; Puente J.; Vidal M.J.M.; Morales-Barrera R.; Villa-Guzman J.C.; Hernando S.; Rodriguez-Vida A.; Gonzalez-del-Alba A.; Mellado B.; Gonzalez-Billalabeitia E.; Olmos D.; Attard G.; De Giorgi U. | 2019-01-01 | EUROPEAN UROLOGY | - | 1.01 Articolo in rivista | - |
| Plasma androgen receptor in prostate cancer | Conteduca V.; Gurioli G.; Brighi N.; Lolli C.; Schepisi G.; Casadei C.; Burgio S.L.; Gargiulo S.;... Ravaglia G.; Rossi L.; Altavilla A.; Farolfi A.; Menna C.; Colangione S.P.; Pulvirenti M.; Romeo A.; De Giorgi U. | 2019-01-01 | CANCERS | - | 1.01 Articolo in rivista | cancers-11-01719.pdf |
| Psychosocial issues in long-term survivors of testicular cancer | Schepisi G.; De Padova S.; De Lisi D.; Casadei C.; Meggiolaro E.; Ruffilli F.; Rosti G.; Lolli C....; Ravaglia G.; Conteduca V.; Farolfi A.; Grassi L.; De Giorgi U. | 2019-01-01 | FRONTIERS IN ENDOCRINOLOGY | - | 1.01 Articolo in rivista | - |